Amplia Therapeutics Limited (ASX:ATX): Narmafotinib Trial Development Across Cancer Indications

Aditi Sarkar

14 October 2026 08:15 PM AEDT

Amplia Therapeutics Limited (ASX:ATX): Narmafotinib Trial Development Across Cancer Indications

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Amplia is developing narmafotinib, an investigational focal adhesion kinase (FAK) inhibitor.
The company announced the first stage of a pivotal narmafotinib trial in May 2026.
An August 2026 collaboration will evaluate narmafotinib alongside olomorasib in lung cancer.
A September 2026 announcement outlined an ovarian cancer trial protocol.
Clinical trial delivery, safety observations and regulatory processes remain central considerations.

Amplia Therapeutics Limited (ASX:ATX) is an Australian biotechnology company developing cancer therapies that inhibit focal adhesion kinase, or FAK. Its lead investigational drug, narmafotinib, is being assessed in oncology programmes involving pancreatic cancer and other tumour types. During 2026, the company reported developments in its clinical trial programme and announced an additional research collaboration, placing the design and execution of those studies at the centre of its operating activities.

Pancreatic Cancer Programme Enters a Further Trial Stage

In May 2026, Amplia Therapeutics (ASX:ATX) announced the launch of the first stage of a pivotal clinical trial involving narmafotinib. The drug is intended to inhibit FAK, a signalling protein associated with the cellular environment surrounding certain tumours. That mechanism is being investigated to understand whether FAK inhibition can contribute to treatment strategies when used with other cancer medicines.

The distinction between a trial commencement and an established clinical outcome is important. Beginning a new study provides a framework for evaluating a treatment; it does not establish efficacy, long-term safety or regulatory approval. Results must be interpreted against the study design and the evidence reported by the company.

Lung Cancer Collaboration Broadens Clinical Research

Amplia Therapeutics (ASX:ATX) announced a clinical trial collaboration and supply agreement with Eli Lilly and Company in August 2026. Under the arrangement, a Phase 1b/2b study is planned to examine narmafotinib in combination with olomorasib, a KRAS G12C inhibitor, in patients with advanced non-small cell lung cancer.

The company stated that the trial is intended to assess safety and efficacy as a second-line treatment, with study commencement planned for late 2026 at sites in Australia and the United States. The collaboration extends clinical investigation of narmafotinib beyond its pancreatic cancer programme. Neither the agreement nor the proposed combination establishes a treatment benefit before trial evidence is available.

Ovarian Cancer Research Adds Another Study Pathway

The company also reported in September 2026 that it had finalised a protocol with the Australia New Zealand Gynaecological Oncology Group for an ovarian cancer trial. For Amplia Therapeutics (ASX:ATX), the announcement indicates a separate clinical research pathway for the same investigational compound. The trial protocol defines how the proposed research will be conducted; outcomes remain subject to enrolment, treatment, follow-up and subsequent reporting.

Clinical and Funding Considerations

Cancer drug development involves clinical recruitment, patient monitoring, data analysis and regulatory review. Trial timelines can change because of safety findings, recruitment patterns or protocol requirements. Amplia Therapeutics (ASX:ATX) must also allocate financial resources among clinical programmes, meaning its reported cash position and expenditure in subsequent company filings are relevant to assessing the pace of research. No unverified cash runway or funding estimate is assumed here.

Key Insights

Amplia Therapeutics (ASX:ATX) entered several distinct clinical development workstreams during 2026, including a pivotal trial stage and collaborations involving additional cancer indications. The common scientific approach is FAK inhibition, but each study has its own patient population, combination treatment and evaluation framework. Their significance rests on the quality of future clinical evidence and the company’s ability to carry out the announced programmes.

FAQs

Q:What does Amplia Therapeutics develop?

A:Investigational oncology therapies, including the FAK inhibitor narmafotinib.

Q:What is narmafotinib?

A:It is an investigational drug designed to inhibit focal adhesion kinase.

Q:What was announced in May 2026?

A:The company reported the launch of the first stage of a pivotal narmafotinib trial.

Q:What does the Lilly collaboration cover?

A:A planned study combining narmafotinib and olomorasib in advanced non-small cell lung cancer.

Q:Has the company established efficacy across these indications?

A:The cited 2026 announcements describe clinical development and study plans, not established efficacy across the indications.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.